I undersøgelser af patienter med pulmonal arteriel hypertension var forekomsten af forhøjede leveraminotransferaser (> 3 × ULN) 12, 7% hos de patienter, som fik bosentan (N = 257), 12, 3% hos de patienter, som fik 125 mg to gange dagligt og 14, 3% hos de patienter, som fik 250 mg to gange dagligt.
In studies in patients with pulmonary arterial hypertension, the incidence of elevated liver aminotransferases (> 3 × ULN) was 12.8% in bosentan-treated patients (N = 257), 12.3% in patients treated with 125 mg twice daily and 14.3% in patients treated with 250 mg twice daily.